Videos

The COVID-19 pandemic has hurt the effort of colorectal cancer screenings.

With dupilumab already available and JAK inhibitors on the way, clinicians have a bevy of treatments designated for pediatric patients.

In consideration of emerging JAK inhibitor options, and the current prescribing availability of baricitinib.

Brett King, MD, PhD, explains the altered screening and care strategies for patients following baricitinib's approval.

Brett King, MD, PhD, discusses the newly available JAK inhibitor—the first systemic therapy approved for the hair-loss condition.

The JAK inhibitor received FDA approval for vitiligo this summer. Investigator now see it as a potent non-steroidal option for eczema.

Christopher Bunick, MD, discusses the future progress of acne management—including a potential mRNA vaccine current in development.

With a broadening array of drug options, involving patients in the care process may be a key to adherence and long-term success.

Christopher Bunick, MD, PhD, reviews the benefit of antibiotic resistance, blood-brain barrier penetration, and digestive distress with agents like sarecycline.

Martha Gulati, MD, joins episode 2 to discuss the burden of gender disparity in cardiovascular research, screening and care.

Dr. Reid Robison, MD, MBA, described his research on clinical depression and the recent acceptance of psychedelic medicine.

Rebecca T. Brown, MD, MPH, describes contributing factors to older homeless adult mortality and future topics of interest in this field.

In the first episode of our monthly series, cardiologists Jorge Plutzky, MD, and Michael Farkouh, MD, interview nephrologist Matthew Weir, MD.

Rebecca T. Brown, MD, MPH, discusses the growing prevalence of older homeless adults, and what diseases community leaders and caregivers are combating most frequently in them.

Treatment adherence remains a concern in psychiatry.

Postpartum depression rates have increased since the COVID-19 pandemic.

Alcohol, stress, drug use, and not seeking help are all risk factors for chronic depression.

CBD has shown promise in treating anxiety and psychosis.

There remains a need for better treatments for bipolar disorder when it is identified early.

Mixed feature depression can be difficult to diagnose because the symptoms can be similar to other psychiatric disorders.

There remains a need for more research into the connection between grief and depression following a death.

Dr. Levine talks with Dr. Lisa Harding about how clinicians can best improve patient care in psychiatry.

Dr. David Hudesman expects drug developers to continue to target biologics for the treatment of IBD.

The Duke expert reviews key strategies for starting and continuing care with the pivotal glycemic control agent.

ALT fluctuations remained stable for patients with NAFLD throughout disease progression.

An Ohio State researcher discusses a new medical center education program for navigating addiction risk in pain patients.

MM-120 is a pharmacologically optimized form of Lysergic acid diethylamide (LSD).

Travis Vandergriff, MD, discusses the unique collaboration with ophthalmologists and urologists in the rare skin condition.